Jiangsu Hualv Biological Technology Co.Ltd. (SHE:300970) — Market Cap & Net Worth
Market Cap & Net Worth: Jiangsu Hualv Biological Technology Co.Ltd. (300970)
Jiangsu Hualv Biological Technology Co.Ltd. (SHE:300970) has a market capitalization of $485.32 Million (CN¥3.32 Billion) as of June 17, 2026. Listed on the SHE stock exchange, this China-based company holds position #12613 globally and #3759 in its home market, demonstrating a 4.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangsu Hualv Biological Technology Co.Ltd.'s stock price CN¥20.90 by its total outstanding shares 158687850 (158.69 Million). Review 300970 total debt and obligations to assess the company's total debt and financial obligations.
Jiangsu Hualv Biological Technology Co.Ltd. Market Cap History: 2021 to 2026
Jiangsu Hualv Biological Technology Co.Ltd.'s market capitalization history from 2021 to 2026. Data shows change from $661.38 Million to $485.32 Million (-12.03% CAGR).
Jiangsu Hualv Biological Technology Co.Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangsu Hualv Biological Technology Co.Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.37x
Jiangsu Hualv Biological Technology Co.Ltd.'s market cap is 0.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.32x
Jiangsu Hualv Biological Technology Co.Ltd.'s market cap is 4.32 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $661.38 Million | $578.09 Million | $15.50 Million | 1.14x | 42.66x |
| 2022 | $403.58 Million | $751.59 Million | $78.25 Million | 0.54x | 5.16x |
| 2023 | $394.86 Million | $996.22 Million | $30.35 Million | 0.40x | 13.01x |
| 2024 | $276.33 Million | $1.03 Billion | -$47.57 Million | 0.27x | N/A |
| 2025 | $476.26 Million | $1.29 Billion | $110.27 Million | 0.37x | 4.32x |
Competitor Companies of 300970 by Market Capitalization
Companies near Jiangsu Hualv Biological Technology Co.Ltd. in the global market cap rankings as of June 17, 2026.
Key companies related to Jiangsu Hualv Biological Technology Co.Ltd. by market ranking:
- Archer-Daniels-Midland Company (NYSE:ADM): Ranked #816 globally with a market cap of $33.40 Billion USD.
- Muyuan Foodstuff Co Ltd (SHE:002714): Ranked #955 globally with a market cap of $28.02 Billion USD ( CN¥191.47 Billion CNY).
- Bunge Limited (NYSE:BG): Ranked #1146 globally with a market cap of $23.11 Billion USD.
- Tyson Foods Inc (NYSE:TSN): Ranked #1549 globally with a market cap of $16.15 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #816 | Archer-Daniels-Midland Company | NYSE:ADM | $33.40 Billion | $78.02 |
| #955 | Muyuan Foodstuff Co Ltd | SHE:002714 | $28.02 Billion | CN¥35.05 |
| #1146 | Bunge Limited | NYSE:BG | $23.11 Billion | $119.42 |
| #1549 | Tyson Foods Inc | NYSE:TSN | $16.15 Billion | $57.24 |
Jiangsu Hualv Biological Technology Co.Ltd. Historical Marketcap From 2021 to 2026
Between 2021 and today, Jiangsu Hualv Biological Technology Co.Ltd.'s market cap moved from $661.38 Million to $ 485.32 Million, with a yearly change of -12.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥485.32 Million | +1.90% |
| 2025 | CN¥476.26 Million | +72.35% |
| 2024 | CN¥276.33 Million | -30.02% |
| 2023 | CN¥394.86 Million | -2.16% |
| 2022 | CN¥403.58 Million | -38.98% |
| 2021 | CN¥661.38 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Jiangsu Hualv Biological Technology Co.Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $485.32 Million USD |
| MoneyControl | $485.32 Million USD |
| MarketWatch | $485.32 Million USD |
| marketcap.company | $485.32 Million USD |
| Reuters | $485.32 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jiangsu Hualv Biological Technology Co.Ltd.
Jiangsu Chinagreen Biological Technology Group Co.,Ltd. engages in the research, development, factory cultivation, and sale of edible fungi in China. It offers Flammulina velutipes; Pleurotus eryngii, including white jade mushroom and oyster mushroom; and Maitake mushrooms. The company was founded in 2010 and is headquartered in Suqian, China.